Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 785
Filter
1.
Multimedia | Multimedia Resources | ID: multimedia-9973

ABSTRACT

Refuerzos de las vacunas Triple Viral para el Sarampión, Rubeola, Paperas y Poliomielitis.


Subject(s)
Vaccines/supply & distribution , Vaccination Coverage/organization & administration , Poliomyelitis/prevention & control , Mumps/prevention & control , Measles Vaccine/administration & dosage
2.
Multimedia | Multimedia Resources | ID: multimedia-9929

ABSTRACT

Definición. Niveles de la cadena de frío. Elementos de un sistema de cadena de frío a nivel local. Conservación y traslado de las vacunas. Preparación de los termos diarios. Estabilidad de las vacunas. Política de frascos abiertos. Eventos adversos asociados a vacunación e inmunizaciones. Clasificación, Registro, Notificación. Anafilaxia. Cadena de frío Conservación y traslado de vacunas. Desvíos. Incidentes. Responsabilidad de les vacunadores Cómo programamos los pedidos de vacunas Vacunación Huéspedes Especiales


Subject(s)
Vaccination , Refrigeration , Vaccines/supply & distribution
9.
Exp Parasitol ; 230: 108170, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34699916

ABSTRACT

Fasciola spp., Opisthorchis spp. and Clonorchis sinensis are common liver flukes that can cause a variety of diseases, mainly cholangiocarcinoma induced by clonorchiasis and liver damage and associated pathology induced by fascioliasis. Because these trematodes are parasites of humans and domestic animals, they have greatly affected the economy of agricultural industries and public health worldwide. Due to the emergence of drug resistance and the living habits of flukes, among other reasons, a possibility of reinfection remains even when antiparasitic drugs are used. Therefore, developing a safe, efficient and cost-effective vaccine against trematodes is an important goal. Here, we briefly describe the progress in the development of vaccines against liver flukes. Related innovations may provide effective protection against these helminths and the diseases that they cause.


Subject(s)
Clonorchis sinensis/immunology , Fasciola hepatica/immunology , Liver Diseases, Parasitic/prevention & control , Opisthorchis/immunology , Vaccines/classification , Animals , Cattle , Clonorchiasis/prevention & control , Fascioliasis/prevention & control , Humans , Opisthorchiasis/prevention & control , Rabbits , Sheep , Vaccines/supply & distribution
11.
Multimedia | Multimedia Resources | ID: multimedia-9006

ABSTRACT

Com o objetivo de ampliar a divulgação de notícias sobre Covid-19 para pessoas com deficiências auditivas, a Coordenação de Comunicação Social (CCS/Fiocruz) lançou um programa semanal que reúne as principais notícias publicadas na Agência Fiocruz de Notícias (AFN) traduzidas para a Língua Brasileira de Sinais (Libras) e com áudio em português.


Subject(s)
Pharmaceutical Raw Material , Vaccines/supply & distribution , Drug Evaluation , Severe Acute Respiratory Syndrome , Scientific Research and Technological Development , Social Media , News , e-Accessibility
12.
Am J Trop Med Hyg ; 105(2): 278-280, 2021 Jun 28.
Article in English | MEDLINE | ID: mdl-34181573

ABSTRACT

As the fight against the coronavirus disease 2019 (COVID-19) pandemic continues, the necessity for wide-scale, global vaccine rollout to reduce the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and slow its mutation rate remains unassailable. The COVID-19 Vaccines Global Access (COVAX) initiative's campaign involves a proportional framework to finance and distribute SARS-CoV-2 vaccines in low- and middle-income countries. However, the COVAX framework has critical limitations, including limited funding and the failure to account for the special epidemic risks and needs of its participating nations, as recommended by the World Health Organization's Strategic Advisory Group of Experts on Immunization framework. These drawbacks disproportionately impact Africa, where many nations rely on COVAX as their main source of vaccines. The current plan to vaccinate only up to 20% of participating nations' populations is short-sighted from both epidemiologic and moral perspectives. COVAX must commit to vaccinating all of Africa and its initiative must be modified to account for the health and economic infrastructures in these countries. Lessons learned from successful vaccination campaigns, including the West African Ebola outbreak, have shown that vaccinating all of Africa is possible and feasible, and that infrastructure and human resources can support mass vaccination. To halt this global pandemic, global responsibility must be accepted to finance and equitably distribute SARS-CoV-2 vaccines to African nations. We urge COVAX to act swiftly to prevent Africa from becoming the new face of a persisting pandemic.


Subject(s)
COVID-19 Vaccines/supply & distribution , COVID-19/prevention & control , Global Health , Mass Vaccination/standards , Vaccines/supply & distribution , Africa/epidemiology , COVID-19/epidemiology , COVID-19 Vaccines/administration & dosage , Humans , Mass Vaccination/methods , Mass Vaccination/statistics & numerical data , Vaccines/administration & dosage , World Health Organization
13.
Pan Afr Med J ; 38: 194, 2021.
Article in English | MEDLINE | ID: mdl-33995800

ABSTRACT

INTRODUCTION: the World Health Organisation (WHO) recommends that countries conduct comprehensive national immunisation program reviews regularly to help them identify systems wide-barriers or gaps and monitor performance against the set targets. METHODS: we reviewed reports from the latest national immunisation program reviews conducted in the 20 countries in the sub-region in the course of 2012-2018. We generated descriptive analysis of the findings across the sub-region. RESULTS: the 20 program reviews included field observations to the subnational levels as well as interviews with program staff and stakeholders. At the time of the reviews, only 11 countries had functional National Immunisation Technical Advisory Groups. Operational funding was inadequate in half of the countries. The reviews documented the cancellation of outreach services, supportive supervision visits and maintenance of cold chain equipment due to the lack of fuel or operational funding. Immunisation programs in 10 countries had major human resource gaps. Vaccine stock management tools were not effectively used in 10 countries, and stock out of vaccines and supplies was documented in 9 countries during the review. The full components of the RED strategy were implemented in only 3 of the 20 countries. Twelve countries reported challenges with the availability and accuracy of target populations. Four countries had documented the presence of vaccine hesitant groups at the time of the reviews. CONCLUSION: the reviews demonstrated challenges in various aspects of the programs in different countries. The implementation of the review recommendations should be built into the annual program plans, as well as into coasted multi-year plans, in order to address the gaps and helps the program to attain the set targets. With the rapid evolution of the scope and complexity of the immunisation programs in recent years, countries should invest their efforts in building the capacity of their human resources as well as updating their logistics and data systems.


Subject(s)
Immunization Programs/organization & administration , Vaccines/supply & distribution , Workforce/statistics & numerical data , Africa, Eastern , Africa, Southern , Capacity Building , Humans , Immunization Programs/statistics & numerical data , Refrigeration , Vaccination Refusal/statistics & numerical data
15.
Multimedia | Multimedia Resources | ID: multimedia-8780

ABSTRACT

A COVID-19 foi responsável por mais de 1.000 mortes de crianças e adolescentes em 2020 no Brasil. O número apresentado é superior a outros países. Neste vídeo, a equipe COVID-19 DivulgAÇÃO Científica conversa com o médico Marco Aurélio Safadi, da Santa Casa de São Paulo, sobre a situação.


Subject(s)
Mortality , Infant Mortality , Coronavirus Infections/mortality , Child , Adolescent , 50334 , Vaccines/supply & distribution , e-Accessibility
16.
Multimedia | Multimedia Resources | ID: multimedia-8781

ABSTRACT

Com o objetivo de ampliar a divulgação de notícias sobre Covid-19 para pessoas com deficiências auditivas, a Coordenação de Comunicação Social (CCS/Fiocruz) lançou um programa semanal que reúne as principais notícias publicadas na Agência Fiocruz de Notícias (AFN) traduzidas para a Língua Brasileira de Sinais (Libras) e com áudio em português.


Subject(s)
Vaccines/supply & distribution , Working Conditions , Health Personnel , Coronavirus Infections/prevention & control , Schools , News , e-Accessibility
17.
Internet resource in Portuguese | LIS -Health Information Locator | ID: lis-48162

ABSTRACT

O ministro da Saúde, Marcelo Queiroga, debateu neste sábado (3/4) com a Organização Mundial da Saúde (OMS) e a Organização Pan-Americana da Saúde (OPAS) uma colaboração técnica para ampliar a capacidade de produção nacional de vacinas no Brasil.


Subject(s)
Vaccines/supply & distribution , World Health Organization , Pan American Health Organization , Production of Products
18.
Multimedia | Multimedia Resources | ID: multimedia-8695

ABSTRACT

A identificação de uma nova linhagem do vírus SARS-CoV-2, causador da COVID-19, preocupa os cientistas e a população. Neste vídeo, a equipe COVID-19 DivulgAÇÃO Científica conversa com a pesquisadora Ana Tereza de Vasconcelos, do Laboratório Nacional de Computação Científica, que aborda os estudos sobre as novas linhagens de SARS-CoV-2 e seus impactos no desenvolvimento de vacinas.


Subject(s)
Coronavirus Infections , Betacoronavirus , Mutation , Vaccines/supply & distribution , e-Accessibility
20.
Global Health ; 17(1): 42, 2021 04 08.
Article in English | MEDLINE | ID: mdl-33832487

ABSTRACT

BACKGROUND: The ongoing pandemic of coronavirus disease 2019 (COVID-19) has the potential to reverse progress towards global targets. This study examines the risks that the COVID-19 pandemic poses to equitable access to essential medicines and vaccines (EMV) for universal health coverage in Africa. METHODS: We searched medical databases and grey literature up to 2 October 2020 for studies reporting data on prospective pathways and innovative strategies relevant for the assessment and management of the emerging risks in accessibility, safety, quality, and affordability of EMV in the context of the COVID-19 pandemic. We used the resulting pool of evidence to support our analysis and to draw policy recommendations to mitigate the emerging risks and improve preparedness for future crises. RESULTS: Of the 310 records screened, 134 were included in the analysis. We found that the disruption of the international system affects more immediately the capability of low- and middle-income countries to acquire the basket of EMV. The COVID-19 pandemic may facilitate dishonesty and fraud, increasing the propensity of patients to take substandard and falsified drugs. Strategic regional cooperation in the form of joint tenders and contract awarding, joint price negotiation and supplier selection, as well as joint market research, monitoring, and evaluation could improve the supply, affordability, quality, and safety of EMV. Sustainable health financing along with international technology transfer and substantial investment in research and development are needed to minimize the vulnerability of African countries arising from their dependence on imported EMV. To ensure equitable access, community-based strategies such as mobile clinics as well as fees exemptions for vulnerable and under-served segments of society might need to be considered. Strategies such as task delegation and telephone triage could help reduce physician workload. This coupled with payments of risk allowance to frontline healthcare workers and health-literate healthcare organization might improve the appropriate use of EMV. CONCLUSIONS: Innovative and sustainable strategies informed by comparative risk assessment are increasingly needed to ensure that local economic, social, demographic, and epidemiological risks and potentials are accounted for in the national COVID-19 responses.


Subject(s)
COVID-19/economics , Drugs, Essential/economics , Drugs, Essential/supply & distribution , Universal Health Care , Vaccines/economics , Vaccines/supply & distribution , Africa , Developing Countries , Health Services Accessibility/statistics & numerical data , Humans , Patient Safety/statistics & numerical data , Prospective Studies , Quality of Health Care/statistics & numerical data , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL
...